| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 6.743 | 13.831 | 11.967 | 17.824 | 24.593 | 30.856 |
| Total Income - EUR | - | - | - | 0 | 6.743 | 13.831 | 11.967 | 17.824 | 24.593 | 30.856 |
| Total Expenses - EUR | - | - | - | 0 | 2.455 | 5.298 | 11.172 | 15.151 | 26.275 | 22.279 |
| Gross Profit/Loss - EUR | - | - | - | 0 | 4.289 | 8.533 | 795 | 2.673 | -1.682 | 8.578 |
| Net Profit/Loss - EUR | - | - | - | 0 | 4.086 | 8.208 | 436 | 2.130 | -2.590 | 6.686 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - R & M Ancarol Med S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 34.303 | 33.189 | 37.715 |
| Current Assets | - | - | - | 0 | 4.204 | 12.435 | 12.954 | 20.917 | 10.301 | 14.304 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 0 | 843 | 4.011 | 1.183 | 1.531 | 2.264 | 5.227 |
| Cash | - | - | - | 0 | 3.362 | 8.424 | 11.772 | 19.386 | 8.036 | 9.077 |
| Shareholders Funds | - | - | - | 0 | 4.129 | 12.259 | 12.423 | 14.591 | 12.041 | 18.660 |
| Social Capital | - | - | - | 0 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 0 | 76 | 176 | 531 | 40.629 | 31.448 | 33.359 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - R & M Ancarol Med S.r.l.